-
1
-
-
0003477486
-
-
IARC Press, Lyon
-
Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
-
(2001)
World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues
-
-
Jaffe, E.S.1
Harris, N.L.2
Stein, H.3
Vardiman, J.W.4
-
2
-
-
0034983045
-
Diagnostic criteria and classification of mastocytosis: a consensus proposal
-
Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (2001) 603-625
-
(2001)
Leuk Res
, vol.25
, pp. 603-625
-
-
Valent, P.1
Horny, H.P.2
Escribano, L.3
-
3
-
-
0034994550
-
Clinical and histopathological aspects of cutaneous mastocytosis
-
Wolff K., Komar M., and Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25 (2001) 519-528
-
(2001)
Leuk Res
, vol.25
, pp. 519-528
-
-
Wolff, K.1
Komar, M.2
Petzelbauer, P.3
-
4
-
-
2642581620
-
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
-
Horny H.P., Sotlar K., Sperr W.R., and Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57 (2004) 604-608
-
(2004)
J Clin Pathol
, vol.57
, pp. 604-608
-
-
Horny, H.P.1
Sotlar, K.2
Sperr, W.R.3
Valent, P.4
-
5
-
-
33745918388
-
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
-
Tournilhac O., Santos D.D., Xu L., et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17 (2006) 1275-1282
-
(2006)
Ann Oncol
, vol.17
, pp. 1275-1282
-
-
Tournilhac, O.1
Santos, D.D.2
Xu, L.3
-
6
-
-
33745899005
-
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders
-
Santos D.D., Hatjiharissi E., Tournilhac O., et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 6 (2006) 478-483
-
(2006)
Clin Lymphoma Myeloma
, vol.6
, pp. 478-483
-
-
Santos, D.D.1
Hatjiharissi, E.2
Tournilhac, O.3
-
7
-
-
0034649716
-
When and how to treat chronic lymphocytic leukemia
-
Dighiero G., and Binet J.L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1799-1801
-
(2000)
N Engl J Med
, vol.343
, pp. 1799-1801
-
-
Dighiero, G.1
Binet, J.L.2
-
8
-
-
33644746629
-
An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL)
-
Horny H.P., Sotlar K., Stellmacher F., Valent P., and Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 59 (2006) 264-268
-
(2006)
J Clin Pathol
, vol.59
, pp. 264-268
-
-
Horny, H.P.1
Sotlar, K.2
Stellmacher, F.3
Valent, P.4
Grabbe, J.5
-
9
-
-
0034759524
-
Systemic mast cell disease associated with B-chronic lymphocytic leukemia
-
Sanz M.A., Valcarcel D., Sureda A., et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica 86 (2001) 1106-1107
-
(2001)
Haematologica
, vol.86
, pp. 1106-1107
-
-
Sanz, M.A.1
Valcarcel, D.2
Sureda, A.3
-
10
-
-
33745863150
-
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial
-
Droogendijk H.J., Kluin-Nelemans H.J., van Doormaal J.J., Oranje A.P., van de Loosdrecht A.A., and van Daele P.L. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107 (2006) 345-351
-
(2006)
Cancer
, vol.107
, pp. 345-351
-
-
Droogendijk, H.J.1
Kluin-Nelemans, H.J.2
van Doormaal, J.J.3
Oranje, A.P.4
van de Loosdrecht, A.A.5
van Daele, P.L.6
-
11
-
-
0034727833
-
Genomic aberrations and survival in chronic lymphocytic leukemia
-
Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
-
(2000)
N Engl J Med
, vol.343
, pp. 1910-1916
-
-
Dohner, H.1
Stilgenbauer, S.2
Benner, A.3
-
12
-
-
4143105617
-
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
-
Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
-
(2004)
N Engl J Med
, vol.351
, pp. 893-901
-
-
Rassenti, L.Z.1
Huynh, L.2
Toy, T.L.3
-
13
-
-
35748931679
-
-
Wierda WG, O'Brien S, Ferrajoli A, et al. Salvage therapy with combined cyclophosphamide (c), fludarabine (f), alemtuzumab (a), and rituximab (r) (cfar) for heavily pre-treated patients with CLL. ASH Annual Meeting Abstracts 2005;106:719.
-
-
-
-
14
-
-
0036202126
-
Abnormal expression of CD antigens in mastocytosis
-
Escribano L., Diaz-Agustin B., Nunez R., Prados A., Rodriguez R., and Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 127 (2002) 127-132
-
(2002)
Int Arch Allergy Immunol
, vol.127
, pp. 127-132
-
-
Escribano, L.1
Diaz-Agustin, B.2
Nunez, R.3
Prados, A.4
Rodriguez, R.5
Orfao, A.6
-
15
-
-
0346880065
-
Clinical, genetic, and therapeutic insights into systemic mast cell disease
-
Tefferi A., and Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11 (2004) 58-64
-
(2004)
Curr Opin Hematol
, vol.11
, pp. 58-64
-
-
Tefferi, A.1
Pardanani, A.2
-
16
-
-
0036204619
-
Surrogate markers of disease in mastocytosis
-
Akin C., and Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 127 (2002) 133-136
-
(2002)
Int Arch Allergy Immunol
, vol.127
, pp. 133-136
-
-
Akin, C.1
Metcalfe, D.D.2
-
17
-
-
33344458341
-
Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis
-
Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., Akin C., and Metcalfe D.D. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 139 (2006) 265-270
-
(2006)
Int Arch Allergy Immunol
, vol.139
, pp. 265-270
-
-
Kushnir-Sukhov, N.M.1
Brittain, E.2
Reynolds, J.C.3
Akin, C.4
Metcalfe, D.D.5
-
18
-
-
0034987848
-
Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders
-
Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 25 (2001) 553-562
-
(2001)
Leuk Res
, vol.25
, pp. 553-562
-
-
Schwartz, L.B.1
-
19
-
-
0028258512
-
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line
-
Kanakura Y., Furitsu T., Tsujimura T., et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 8 Suppl. 1 (1994) S18-S22
-
(1994)
Leukemia
, vol.8
, Issue.SUPPL. 1
-
-
Kanakura, Y.1
Furitsu, T.2
Tsujimura, T.3
-
20
-
-
27244451794
-
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
-
Elter T., Borshmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031
-
(2005)
J Clin Oncol
, vol.23
, pp. 7024-7031
-
-
Elter, T.1
Borshmann, P.2
Schulz, H.3
|